TME Pharma Secures €500,000 through New Bond Issue

TME Pharma N.V. has initiated a new bond issue to raise €500,000, aimed at boosting its financial capacity and supporting its investment strategy. The bonds, with a maturity of nine months, will be issued at 85.4% of nominal value and repayable at 93.5% at maturity. Additionally, private warrants could potentially add €702,576 to the funds, if exercised. A key investor has committed €427,000, reflecting significant shareholder confidence.

CEO Diede van den Ouden emphasized the importance of this funding for advancing TME Pharma's projects and adapting to a new strategic focus. The company has focused on reducing costs and leveraging outsourcing, resulting in more direct financing for its core activities. This move is part of a broader effort to enhance profitability while safeguarding its main therapeutic assets.